EC Number   |
Protein Variants |
Reference |
|---|
   2.7.11.16 | A142V |
expression of the GRK4gamma mutant in transgenic mice leads to development of hypertension and lack of D1 agonist-induced diuresis and natriuresis in the mice |
662921 |
| 2.7.11.16 | A142V |
naturally occuring functional polymorphism, the mutation leads to increased GRK4 activity and phosphorylation of dopamine receptors, phenotype |
671205, 671342 |
| 2.7.11.16 | A142V |
the mutation is associated with hypertension |
738655 |
| 2.7.11.16 | A486V |
naturally occuring functional polymorphism, the mutation leads to increased GRK4 activity and phosphorylation of dopamine receptors, phenotype |
671205, 671342 |
| 2.7.11.16 | A486V |
the mutation is associated with hypertension. There is an increased rate of autophosphorylation of a number of residues in the mutant relative to the wild type enzyme |
738655 |
| 2.7.11.16 | C561S/C562S/C565S |
site-directed mutagenesis, mutation of palmitoylation sites, the mutant protein retains its ability to phosphorylate rhodopsin, albeit with a 5fold higher Km and 2fold lower Vmax compared with those of wild-type GRK6 |
674574 |
| 2.7.11.16 | F527D |
site-directed mutagenesis, mutant structure in comparison to the wild-type enzyme |
674574 |
| 2.7.11.16 | G298S |
the complete loss-of-function variant is identified in heterotaxy patients |
762419 |
| 2.7.11.16 | I165E |
site-directed mutagenesis, mutant structure in comparison to the wild-type enzyme |
674574 |
| 2.7.11.16 | I165E/F527D |
site-directed mutagenesis, mutant structure in comparison to the wild-type enzyme |
674574 |
